PTB Proteins Induce RNA Looping
Lamichhane, Daubner et al., PNAS
Researchers in the US and Switzerland report that polypyrimidine tract-binding proteins induce RNA looping ― a finding they deduced using FRET, NMR spectroscopy, and in vivo splicing data. They show that two PTB RNA recognition motifs can bind two distant pyrimidine tracts, bringing their 5' and 3' ends in close proximity, thus inducing loop formation.
Vermillion, Quest Diagnostics Launch OVA1 Ovarian Cancer Test
Vermillion also reformed its scientific advisory board this week and told ProteoMonitor that it is in the process of trying to get relisted on the Nasdaq exchange.
March 10, 2010
Clinical Trial Using Proteomics Technologies for Personalized Medicine Approach to Breast Cancer
The trial is using technologies from Caris Life Sciences and George Mason University's Center for Applied Proteomics and Molecular Medicine to create proteomic profiles to determine which therapies work best for each individual patient.
March 09, 2010
NCI-CPTC, AACC Agreement Aims to Advance Proteomics in Clinical Labs
The alliance aims to take proteomics into the clinical chemistry lab and to encourage proteomics researchers to adopt procedures and processes that are routinely practiced in clinical chemistry labs.
March 09, 2010
Included is a method for classifying spectra to determine the prevalence of a condition; a method and system for analyzing whole proteins; and biomarkers for cancers and amyloid-associated diseases.
March 08, 2010
Proteomics Received $375.5M in NIH Funds in FY 2009, Including $55M in Stimulus Funds
The big winners in the funding sweepstakes include Rolf Apweiler, Richard Smith, projects to establish proteomics centers, and biomarker-based research.
March 05, 2010
Also at the conference, Agilent and Bruker introduced new mass specs, Thermo Fisher trumpeted its newest MS platforms, and Waters continued pushing its Acquity UPLC.
March 05, 2010
Technology Developed by Liotta and Petricoin Used to Test Chloroquine to Treat Breast Cancer
The research will use reverse-phase protein microarray technology developed by Liotta and Petricoin to create a proteomic profile of tissue samples from trial participants in order to show which protein pathways or drug targets are activated, and then determine whether chloroquine has any effect as a treatment.
March 05, 2010
Ubiquigent Formed to Commercialize Products for Ubiquitylation Research
Ubiquigent is operating as a subsidiary of Stemgent, and will produce biological products and services generated by the Scottish Institute for Cell Signaling at the University of Dundee.
March 05, 2010
APT Therapeutics Says EPO to Grant Patent Covering Site-specific Protein Modification
Potential applications for the method include the creation of "entirely new classes of therapeutic proteins" and new versions of off-patent proteins, APT said.
March 05, 2010
Ten Highest NIH Awards for Proteomics for FY 2009
The NIH awarded at least $356.5 million in more than 1,000 grants for proteomics research in fiscal 2009. ProteoMonitor looks at the 10 projects that received the most funding during the year.
March 05, 2010
Transgenomic Sues Power3 for Libel, Slander, Breach of Contract in Protein Biomarker Deal
The lawsuit, filed this week in US District Court in Nebraska, stems from a deal signed last year to develop and commercialize Power3's biomarker tests for neurodegenerative diseases.
February 26, 2010
